Although increased patenting has accompanied the development of antivirals as in vivo therapeutics, ongoing US litigation reflects concerns regarding their patentability.
This is a preview of subscription content, log in via an institution to check access.
References
USPTO. Manual of Patent Examining Procedure, 8th ed., rev. 4, §2164 (USPTO, Alexandria, VA, USA, 2007).
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988), quoting Ansul Co. v. Uniroyal, Inc., 448 F.2d 872, 878-79 (2d Cir. 1971), cert. denied, 404 US 1018 (1972).
PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558, 1564 (Fed. Cir. 1996).
Ex Parte Vasquez, 2002 WL 465382 at 4-7 (BPAI).
Dionne v. Liotta, 2001 WL 34373630 at 5-6 (BPAI).
Ex Parte Jarvest, 2001 WL 3581155 at 4 (BPAI).
USPTO. Manual of Patent Examining Procedure, 8th ed., rev. 4 §2149 (USPTO, Alexandria, VA, USA, 2007).
Graham v. John Deere Co. of Kansas City, 383 US 1, 17–18 (1966).
KSR International Co. v. Teleflex Inc., 127 S.Ct. 1727 (2007).
Teitelbaum, R. & Cohen, M. Nat. Biotechnol. 25, 1105–1106 (2007).
Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc., No. 05 Civ. 1887 (D.NJ Sept. 6, 2007), 2007 WL 2669338.
Id.
Id.
Yeh, B.T. CRS Report for Congress: Influenza Antiviral Drugs and Patent Law Issues (Congressional Research Services, Washington, DC, USA, 2005).
US Constitution, Amendment V.
28 USC §1498(a) (2007).
In re Strahilevitz 668 F.2d 1229, 1232 (CCPA 1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lu, D., Collison, A. & Kowalski, T. Patentability issues surrounding antivirals. Nat Biotechnol 25, 1403–1404 (2007). https://doi.org/10.1038/nbt1207-1403
Issue Date:
DOI: https://doi.org/10.1038/nbt1207-1403
- Springer Nature America, Inc.